# Daiichi-Sankyo

**Type:** Funders  
**Canonical URL:** https://scholariq.org/funders/daiichi-sankyo/

## Facts

| Field | Value |
| --- | --- |
| Country | JP |
| Description | Japanese pharmaceutical company |
| OpenAlex ID | https://openalex.org/F4320321625 |
| ROR ID | https://ror.org/027y26122 |
| Works | 7,367 |

## Funder papers

- [Safety and Efficacy of Eplerenone in Patients at High Risk for Hyperkalemia and/or Worsening Renal Function](https://scholariq.org/papers/safety-and-efficacy-of-eplerenone-in-patients-at-high-risk-for-hyperkalemia-and/)
- [Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial](https://scholariq.org/papers/niraparib-first-line-maintenance-therapy-in-patients-with-newly-diagnosed/)
- [Effect of Patiromer on Reducing Serum Potassium and Preventing Recurrent Hyperkalaemia in Patients with Heart Failure and Chronic Kidney Disease on Raas Inhibitors](https://scholariq.org/papers/effect-of-patiromer-on-reducing-serum-potassium-and-preventing-recurrent/)
- [Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF](https://scholariq.org/papers/initial-decline-dip-in-estimated-glomerular-filtration-rate-after-initiation-of/)
- [The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study](https://scholariq.org/papers/the-effect-of-intravenous-ferric-carboxymaltose-on-health-related-quality-of/)
- [Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial](https://scholariq.org/papers/effects-of-empagliflozin-on-progression-of-chronic-kidney-disease-a-prespecified/)
- [Correlates and Consequences of an Acute Change in eGFR in Response to the SGLT2 Inhibitor Dapagliflozin in Patients with CKD](https://scholariq.org/papers/correlates-and-consequences-of-an-acute-change-in-egfr-in-response-to-the-sglt2/)
- [High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni Syndrome](https://scholariq.org/papers/high-prevalence-of-somatic-oncogenic-driver-alterations-in-patients-with-nsclc/)
- [Double-Blind, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Eplerenone in Japanese Patients With Chronic Heart Failure (J-EMPHASIS-HF)](https://scholariq.org/papers/double-blind-randomized-placebo-controlled-trial-evaluating-the-efficacy-and/)
- [Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy](https://scholariq.org/papers/small-cell-transformation-in-egfr-mutated-non-small-cell-lung-cancer-dll3/)
- [Genetic background, recent advances in molecular biology, and development of novel therapy in Alport syndrome](https://scholariq.org/papers/genetic-background-recent-advances-in-molecular-biology-and-development-of-novel/)
- [Efficacy and safety of esaxerenone vs trichlormethiazide for the treatment of uncontrolled essential hypertension in Japanese patients with type 2 diabetes mellitus: a subanalysis of the EXCITE-HT study](https://scholariq.org/papers/efficacy-and-safety-of-esaxerenone-vs-trichlormethiazide-for-the-treatment-of/)
- [ARAF Amplification in Small-Cell Lung Cancer-Transformed Tumors Following Resistance to Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitors](https://scholariq.org/papers/araf-amplification-in-small-cell-lung-cancer-transformed-tumors-following/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.